<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Oto, Ali</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">GSA Holds Promise for Treatment of Hypertrophic Obstructive Cardiomyopathy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">28-29</style></pages><abstract><style  face="normal" font="default" size="100%">Cyanoacrylates are the main liquid adhesives used in the vascular system and have an important role in managing vascular abnormalities, especially arteriovenous malformations [Pollack JS, White RI, Jr. J Vasc Interv Radiol 2001]. This article discusses the use of glue septal ablation treatment for hypertrophic obstructive cardiomyopathy.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>